Episode Details
Back to Episodes
Weekend Round Up March 08, 2026: Gilead's $7.8B CAR-T Bet; Servier Acquires Day One for $2.5B
Published 4 months, 2 weeks ago
Description
This week, the pharma industry stacked three of the year's biggest deals in five days — and the FDA quietly told us something important about what happens when gene therapy evidence packages get thin. Meanwhile, the GLP-1 wars got more expensive for everyone not named Novo or Lilly. Let's take it apart.